pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Response rates above 50% in PD-1 high/intermediate patients with no liver tox surprises could set up for a potential acquisition.”

Pharma 101

Pharma Biopharma FDA Competition 101

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.

Competition 90

Competition Marketing Pharma Biopharma 90

Impetus Digital

MARCH 15, 2024

In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. However, with rapid growth comes growing pains.

Recruitment 78

Recruitment Healthcare Provider Patients Healthcare 78

MedCity News

JUNE 16, 2023

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 106

Pharma Food and Drug Administration Recruitment Pharmacology 106

PM360

MAY 10, 2024

Before that, she was the head of omnichannel strategy at Ionis Pharma and held senior digital roles at various healthcare and biopharma companies. Throughout her career, Zara has leveraged human-centered innovation to empower people and to realize her commitment to improve healthcare access for patients with unmet needs.

Healthcare 52

Healthcare Healthcare Biopharma Engineering 52

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

Pharmaceutical Technology

JUNE 15, 2023

AI in pharma R&D is one of the latest innovations helping teams apply existing knowledge to new problems. Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. Here are a few ways AI is used in pharma today.

Pharma 52

Pharma Management Networking Manufacturing 52

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., This is supported by epidemiology data from Evaluate Pharma. Europe, and parts of Asia.

Marketing 59

Marketing Biopharma Government Pharma 59

Pharmaceutical Technology

JUNE 29, 2022

Meanwhile, the pharma industry is undergoing somewhat of a transformation itself. Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. That is a key competitive advantage,” says Laursen. “We

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. The second to increase in patient-oriented communication and support for physicians.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

MAY 14, 2024

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. Competition is expected to intensify in the next few years as both Novo Nordisk and Eli Lilly plan to launch their respective weight-loss drugs in Mainland China.

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

MedCity News

AUGUST 3, 2022

Alnylam Pharmaceuticals drug Onpattro, an FDA-approved treatment for nerve pain caused by hereditary transthyretin amyloidosis, now has Phase 3 data showing it can also help the much larger group of patients suffering heart problems from the rare protein disease.

FDA 90

FDA Competition Pharmaceutical Patients 90

European Pharmaceutical Review

DECEMBER 19, 2022

Nonetheless, some stakeholders remain concerned with this new approach given the complexity of biological medicines and the need for patients to be treated individually and have called for further discussions with regulators and all stakeholders. What are the concerns about the interchangeability of biosimilars?

Medicine 52

Medicine Biopharma Safety Food 52

pharmaphorum

JANUARY 27, 2023

While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.”

Pharma 52

Pharma Manufacturing Biopharma Medicine 52

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Clarivate

OCTOBER 25, 2023

The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs. Impact for patients taking the diabetes drugs and blood thinners might be less noticeable since these drugs tend to receive coverage as preferred brand tiers with copays.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

MAY 8, 2024

Doubling down on strategic therapeutic areas Pharma once again finds itself having to narrow its sights on partnerships that deliver the next blockbuster and enable differentiation from the competition—all while navigating increasing regulatory scrutiny and shifting patient and payer expectations.

Pharma 59

Pharma Biopharma Prospecting Competition 59

Clarivate

SEPTEMBER 26, 2023

One of the critical factors determining the success of a clinical trial is the selection of appropriate clinical sites that have evidenced access to specific patient populations. Patient recruitment accounts for 32% of all trial costs and patient drop out averages 18%, according to Deloitte figures. Food and Drug Administration.

Food and Drug Administration 59

Food and Drug Administration Electronics Patients Healthcare 59

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52

Retail Healthcare Healthcare Physicians 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. In January 2023, VillageMD acquired Summit Health for $8.9

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Positive outcomes in a key patient segment could broaden TRODELVY’s uptake in metastatic breast cancer. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

Clarivate

MAY 24, 2023

Food and Drug Administration advisory committee’s narrow 8-6 vote in favor of recommending accelerated approval for a first-in-class gene transfer therapy was welcomed by Duchenne muscular dystrophy (DMD) patients and caregivers. Most patients must use a wheelchair by the time they are in their teens.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

Clarivate

DECEMBER 1, 2021

Clarivate experts share takeaways from the 2021 American Heart Association Scientific Sessions (AHA21) , with insights on how findings may impact patient care. What’s new from AHA21: In this subanalysis of the EMPEROR-Preserved trial, empagliflozin was shown to be effective in patients with preserved LVEF of ?

Safety 52

Safety Patients Management Marketing 52

Pharmaceutical Technology

MARCH 24, 2023

New Developments for TB In a recent Phase I clinical trial (NCT03722472), researchers have been able to test the first thermostable TB vaccine in patients. In this trial, patients were given a thermostable version of the vaccine or a non-thermostable vaccine in two treatment regimens.

Pharma 64

Pharma Side effects Marketing Biopharma 64

Pharmaceutical Technology

MARCH 21, 2023

In this month’s edition, which covers events from late January to early March, manufacturing contract-related data from GlobalData’s PharmSource reports and news from GlobalData’s Pharma Intelligence Center have been collated to identify stakeholders at the center of new developments.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

JANUARY 25, 2023

In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. In such times, experts expect partnerships between biotechs and big pharma, like the Anima Biotech/AbbVie deal announced earlier this month , to become even more popular.

Marketing 69

Marketing Biopharma Pharma Competition 69

Pharmaceutical Technology

JANUARY 15, 2023

In order to get a therapy to the market, pharma companies often outsource the drug manufacturing to specialist contract manufacturing organizations (CMOs). While Catalent Inc and PCI Pharma Services are in charge of the solid dose and packaging of Lupkynis, Lonza is manufacturing the small molecule API.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52

Pharmaceutical Technology

APRIL 16, 2023

By shifting injections from clinics to living rooms, these single-use, ready-to-use devices have improved the patient experience and supported treatment adherence for an array of common chronic diseases. However, patients with conditions requiring higher doses, such as cancer, have yet to enjoy these benefits. The closed system.

Medical 52

Medical Medicine Patients Manufacturing 52

Pharmaceutical Technology

JUNE 16, 2023

Synthetic biology biopharma Biostar Pharma announced is ready to advance its utidelone injectable (UTD1) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), following approval from the US Food and Drug Administration (FDA) for the study. as the secondary endpoints. as the secondary endpoints.

FDA 52

FDA Food and Drug Administration Patients Marketing 52

Pharmaceutical Technology

FEBRUARY 27, 2023

To identify key events from late December to late January, this news service collated manufacturing contract-related data from PharmSource reports, and news from GlobalData’s Pharma Intelligence Center, to identify participants that are likely to experience an impact following the news.

Manufacturing 52

Manufacturing Pharmaceutical Pharma FDA 52